-
Weiss R, Potter J, Griffin M, et al. Long-term outcomes from the National Drug Abuse Treatment Clinical Trials Network Prescription Opioid Addiction Treatment Study. Drug Alcohol Depend. 2015. PMCID: PMC4407806. PMID: 25818060.
-
Ling W, Hillhouse M, Domier C, et al. Buprenorphine Tapering Schedule and Illicit Opioid Use. Addiction. 2009;104(2):256-265. PMCID: PMC3150159. PMID: 19149822.
-
SAMHSA. Sublingual and Transmucosal Buprenorphine for Opioid Use Disorder: Review and Update. Winter 2016.
-
ASAM. The ASAM National Practice Guideline For the Treatment of Opioid Use Disorder 2020 Focused Update. 2020.
-
SAMHSA/CSAT. Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction. 2004. PMID: 22514846.
-
FSMB. Model Policy on DATA 2000 and Treatment of Opioid Addiction in the Medical Office. FSMB Website. 2013.
-
Mackey K, Veazie S, Anderson J, Bourne D, Peterson K. Barriers and Facilitators to the Use of Medications for Opioid Use Disorder: A Rapid Review. J Gen Intern Med. December 2020;35(Suppl 3):954-963. doi:10.1007/s11606-020-06257-4. PMCID: PMC7728943. PMID: 33145687.
-
McNicholas L. Buprenorphine: Induction, Dosing and Related Issues. American Psychiatric Association Sponsored Webinar; 2011.
-
Kosten T, George T. The Neurobiology of Opioid Addiction: Implications for Treatment. NIDA Sci Pract Perspect. 2002;1(1):13-20. PMCID: PMC2851054. PMID: 18567959.
-
Fiellin D, Schottenfeld R, Cutter C, et al. Primary Care-Based Buprenorphine Taper vs Maintenance Therapy for Prescription Opioid Dependence: A Randomized Clinical Trial. JAMA Intern Med. 2014;174(12):1947-1954.
-
Weiss R, Potter J, Fiellin D. Adjunctive Counseling During Brief and Extended Buprenorphine-Naloxone Treatment for Prescription Opioid Dependence. Arch Gen Psychiatry. 2012;68(12):1238-1246. PMCID: PMC3470422. PMID: 22065255.
-
FDA. FDA approves first buprenorphine implant for treatment of opioid dependence. FDA News Events. May 26, 2016.
-
ASAM. The ASAM National Practice Guideline For the Use of Medications in the Treatment of Addiction Involving Opioid Use. June 1, 2015.
-
Kraus M, Alford D, Kotz M, et al. Statement of the American Society of Addiction Medicine Consensus Panel on the Use of Buprenorphine in Office-Based Treatment of Opioid Addiction. J Addict Med. 2011;5(4):254-263.
-
Substance Abuse and Mental Health Services Administration (SAMHSA). About Buprenorphine Therapy. 2011.
-
Farmer C, Lindsay D, Williams J, et al. Practice Guidelines for Burprenorphine for the Treatment of Opioid Use Disorders: Results of an Expert Panel Process. 2015;36(2).
-
NIDA. Principles of drug addiction treatment: A research-based guide (Third Edition_. January 2018.
-
USDHHS. Medication Assisted Treatment for Opioid Use Disorders Reporting Requirements. 2016.
-
Emrick CD. Alcoholics Anonymous and Other 12-Step Groups. Textb Subst Abuse Treat. 1999:403-411.
-
ASAM. 2020 National Practice Guideline. Am Soc Addict Med. 2020.
-
Raouf M, Bettinger JJ, Fudin J. A Practical Guide to Urine Drug Monitoring. Fed Pract. April 2018;35(4):38-44. PMCID: PMC6368048. PMID: 30766353.
-
Gourlay D, Heit H, Caplan Y. Urine Drug Testing in Clinical Practice: The Art and Science of Patient Care. Johns Hopkins Med. 2012;5.
-
FDA. CLIA – Clinical laboratory improvement amendments – currently waived analytes. 2021.
-
Christo P, Manchikanti L, Ruan X, et al. Urine Drug Testing In Chronic Pain. Pain Physician. 2011;14:123-143. PMID: 21412368.
-
TransMed. CLIA Screen In-Vitro (CSI) 12-Panel Drug Test Screening Cup CLIA Waived. TransMed Drug Test Lab Supplies. 2018.
-
Finch J, Kamien J, Amass L. Two-Year Experience with Buprenorphine-Naloxone (Suboxone) for Maintenance Treatment of Opioid Dependence within a Private Practice Setting. J Addict Med. 2014;1(2):104-110. PMID: 21768942.
-
Nixon LL, Marlinga JC, Hayden KA, Mrklas KJ. Barriers and Facilitators to Office-Based Opioid Agonist Therapy Prescribing and Effective Interventions to Increase Provider Prescribing: Protocol for a Systematic Review. Syst Rev. July 25, 2019;8(1):186. doi:10.1186/s13643-019-1076-7. PMCID: PMC6657163. PMID: 31345258.
-
Soyka M. Buprenorphine and Buprenorphine/Naloxone Intoxication in Children — How Strong Is the Risk?. Curr Drug Abuse Rev. 2013;6(1):63-70.
-
Drug Enforcement Administration (DEA). Buprenorphine. 2019.
-
SAMHSA Press Office. Sharp rise in buprenorphine-related emergency department visits from 2005 to 2010. 2013.
-
Martin T, Rocque M. Accidental and Non-Accidental Ingestion of Methadone and Buprenorphine in Childhood: A Single Center Experience, 1999-2009. Curr Drug Saf. 2009;6:12-16.
-
Indivior Inc. Suboxone Highlights of Prescribing Information. http://www.suboxone.com/. December 2016.
-
Food and Drug Administration (FDA). Buprenorphine-containing Transmucosal products for Opioid Dependence (BTOD) Risk Evaluation and Mitigation Strategy (REMS). Initial REMS / , updated 6/2015 2013.
-
FDA Drug Safety Communication: FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning. US Food Drug Adm Cent Drug Eval Res. August 31, 2016.
-
FDA Drug Safety Communication: FDA urges caution about withholding opioid addiction medications from patients taking benzodiazepines or CNS depressants: careful medication management can reduce risks. US Food Drug Adm Cent Drug Eval Res. September 20, 2017.
-
Wartenberg A. Management of Buprenorphine Side Effects. 2013.
-
RxList. Oxazepam (Oxazepam Tablets): Side Effects, Interactions, Warning, Dosage & Uses. RxList. 2017.
-
RxList. Ativan (Lorazepam): Side Effects, Interactions, Warning, Dosage & Uses. RxList. 2017.
-
RxList. Diazepam (Diazepam Tablets): Side Effects, Interactions, Warning, Dosage & Uses. RxList. 2017.
-
Drugs.com. Naloxone. Drugs.com. January 6, 2021.
-
Irwin R, Rippe J. Irwin and Rippe’s Intensive Care Medicine. Lippincott Williams & Wilkins; 2012.
-
BMJ. Benzodiazepine overdose. 2017.
-
SAMHSA. Opioid Overdose Prevention Toolkit | SAMHSA Publications. SAMHSA. June 2018.
-
Morasco B, Cavanagh R, Gritzner S, et al. Care Management Practices for Chronic Pain in Veterans Prescribed High Doses of Opioid Medications. Farm Pract. 2013;6:671-678. PMCID: PMC2972371. PMID: 20801580.
-
Jones H, Fischer G, Heil S. Maternal Opioid Treatment: Human Experimental Research (MOTHER) – Approach, Issues and Lessons Learned. Addiction. 2012;107:28-35.
-
Daitch D, Daitch J, Novinson D, et al. Conversion from High-Dose Full-Opioid Agonists to Sublingual Buprenorphine Reduces Pain Scores and Improves Quality of Life for Chronic Pain Patients. Pain Med. 2014;15(12):2087-2094. PMID: 25220043.
-
Waknine Y. FDA Approves 7-Day Buprenorphine Pain Patch. 2010.
-
FDA. Medication Guide: ButransTM CIII (buprenorphine) Transdermal System. 2010.
-
Purdue Pharma. Butrans – buprenorphine patch, extended release. 2019.
-
Davis M. Twelve reasons for considering buprenorphine as a frontline analgesic in the management of pain. SupportiveOncology.net. 2012.
-
Fiellin D. Treatment of acute pain in patients receiving buprenorphine/naloxone. March 9, 2014.
-
Alford D, Labelle C, Kretsch N, et al. Collaborative Care of Opioid-Addicted Patients in Primary Care Using Buprenorphine: Five-Year Experience. Arch Intern Med. 2011;171(5):425-431.
-
Alford D, Compton P, Samet J. Acute Pain Management for Patients Receiving Maintenance Methadone or Buprenorphine Therapy. Ann Intern Med. 2006;144(2):127-134. PMCID: PMC1892816. PMID: 16418412.
-
Stephenson D, SAM Committee on Treatment of Opioid Dependence. Guidelines for Physicians Working in California Opioid Treatment Programs. 2008.
-
Weiss RD, Potter JS, Copersino ML, et al. Conducting Clinical Research with Prescription Opioid Dependence: Defining the Population. Am J Addict. April 2010;19(2):141-146. doi:10.1111/j.1521-0391.2009.00017.x. PMCID: PMC2852106. PMID: 20163386.
-
VA/DoD. Management of Substance Use Disorder (SUD) (2015) – VA/DoD Clinical Practice Guidelines. 2015.
-
Melemis S. Relapse Prevention and the Five Rules of Recovery. Yale J Biol Med. 2015;88:3. PMCID: PMC4553654. PMID: 26339217.
-
Department of Veterans Affairs, Department of Defense. VA/DoD Clinical Practice Guideline for the Management of Substance Use Disorders Stabilization Pocket Card. 2015.
-
Nielsen S, Hillhouse M, Thomas C. A Comparison of Buprenorphine Taper Outcomes between Prescription Opioid and Heroin Users. J Addict Med. 2013;7(1):33-38. PMCID: PMC3567310. PMID: 23222095.
-
Dunn K, Sigmon S, Strain E. The Association between Outpatient Buprenorphine Detoxification Duration and Clinical Treatment Outcomes: A Review. Drug Alcohol Depend. 2011;119(1-2):1-9. PMCID: PMC3205338. PMID: 21741781.
